Regenerative Medicine Market

The regenerative medicine market is projected to reach USD 49.0 Billion by 2028 from USD 16.0 Billion in 2023, at a CAGR of 25.1% during the forecast period. The uphill rise of the regenerative medicine market can be credited to the personalized medicine, emerging applications in new therapeutic areas, increasing collaborations and partnerships by major market players and increasing regulatory approvals in regenerative medicine.

The global regenerative medicine market is highly competitive with multiple companies competing for high market shares. The prominent players operating in this market include Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), and CORESTEM, Inc (South Korea) among others.

To know about the assumptions considered for the study download the pdf brochure

Novartis AG (Switzerland)

Novartis AG is a healthcare company that focuses on discovering, developing, manufacturing, and marketing innovative as well as generic pharmaceuticals and biotechnology products. The company operates in two segments—Innovative Medicines (patent-protected prescription medicines) and Sandoz (generic pharmaceuticals and biosimilars). Novartis offers regenerative medicine products through its Innovative Medicines segment. The company’s products are major contributors to the regenerative medicine market. The company also has a strong geographic presence with distribution channels across North America, Europe, Asia Pacific, Latin America, and Africa. The company also focuses on collaborating with other market players over the years, which supports its leading position in the regenerative medicine market.

Biogen, Inc. (US)

Biogen is a global biopharmaceutical company involved in discovering, developing, manufacturing, and marketing therapies for neurological and neurodegenerative diseases. The company focuses on indications such as multiple sclerosis (MS) and Alzheimer’s disease. Biogen’s pipeline focuses on therapeutic areas, such as neurology, neuropsychiatry, specialized immunology, and rare diseases. The company operates as one operating segment. Few examples of the company’s products in pipeline include BIIB080 (tau ASO) – Alzheimer’s disease and Tofersen (SOD1) – SOD1-amyotrophic lateral sclerosis (ALS), among others.

Gilead Sciences, Inc. (US)

Gilead is a research-based biopharmaceutical company involved in developing, manufacturing, and marketing novel medicines. The company operates in a single business segment. Based on products, the company’s revenue can be divided into HIV, HCV, HBV/ HDV, Cell Therapy, VELDURY, TRODELVY, and others.  YESCARTA (axicabtagene ciloleucel) and TECARTUS (brexucabtagene autoleucel) are the FDA-approved regenerative medicine products offered by the company. These products are used for oncology indications. The major strengths of the company include a wide geographic reach and strong brand image. The company has a geographic presence across 35 countries, with a strong distribution network.

Sarepta Therapeutics, Inc.

Sarepta is a commercial-stage biopharmaceutical company focused on discovering, developing, and marketing unique RNA-targeted therapeutics to treat rare diseases. The company operates as a single business unit. The company focuses on offering precision genetic medicines, which are a part of the regenerative medicine market. Currently, the company has pipeline candidates focusing on Duchenne Muscular Dystrophy, Limb-Girdle Muscular Dystrophies, Charcot-Marie-Tooth Neuropathies, and Pompe disease.

Related Reports:

Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]